Year-in-review 2009: Asthma, COPD and airway biology

Respirology

Volumn 15, Issue 2, 2010, Pages 365-376

  Reddel, Helen K ^a   Upham, John W ^b   Salvi, Sundeep S ^c   Yang, Ian A ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Chest Research Foundation   (India)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Clinical medicine; Pathogenesis

Indexed keywords

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; GENOMICS; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PATIENT MONITORING; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

AIRWAY REMODELING; ASTHMA; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 76249129373     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01702.x     Document Type: Review

References (131)

1. Rodriguez E, Baurecht H, Herberich E et al. Meta-analysis of filaggrin polymorphisms in eczema and asthma: robust risk factors in atopic disease. J. Allergy Clin. Immunol. 2009 123: 1361 1370 e1367.
2. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009 339: b2433.
3. He JQ, Hallstrand TS, Knight D et al. A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness. J. Allergy Clin. Immunol. 2009 124: 222 229.
4. Weiss ST, Raby BA, Rogers A. Asthma genetics and genomics 2009. Curr. Opin. Genet. Dev. 2009 19: 279 282.
5. Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am. J. Respir. Crit. Care Med. 2009 180: 388 395.
6. McKinley L, Alcorn JF, Peterson A et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J. Immunol. 2008 181: 4089 4097.
7. Calderon C, Rivera L, Hutchinson P et al. T-cell cytokine profiles are altered in childhood asthma exacerbation. Respirology 2009 14: 264 269.
8. Matsumoto K, Inoue H, Fukuyama S et al. Frequency of Foxp3+CD4CD25+ T cells is associated with the phenotypes of allergic asthma. Respirology 2009 14: 187 194.
9. Kamijo S, Takai T, Kuhara T et al. Cupressaceae pollen grains modulate dendritic cell response and exhibit IgE-inducing adjuvant activity in vivo. J. Immunol. 2009 183: 6087 6094.
10. Yerkovich ST, Roponen M, Smith ME et al. Allergen-enhanced thrombomodulin (blood dendritic cell antigen 3, CD141) expression on dendritic cells is associated with a TH2-skewed immune response. J. Allergy Clin. Immunol. 2009 123: 209 216 e204.
11. Rate A, Upham JW, Bosco A et al. Airway epithelial cells regulate the functional phenotype of locally differentiating dendritic cells: implications for the pathogenesis of infectious and allergic airway disease. J. Immunol. 2009 182: 72 83.
12. Upham JW, Zhang G, Rate A et al. Plasmacytoid dendritic cells during infancy are inversely associated with childhood respiratory tract infections and wheezing. J. Allergy Clin. Immunol. 2009 124: 707 713 e702.
13. Li L, Kong L, Fang X et al. SH2-B beta expression in alveolar macrophages in BAL fluid of asthmatic guinea pigs and its role in NGF-TrkA-mediated asthma. Respirology 2009 14: 60 8.
14. Gao FS, Qiao JO, Zhang Y et al. Chronic intranasal administration of Aspergillus fumigatus spores leads to aggravation of airway inflammation and remodelling in asthmatic rats. Respirology 2009 14: 360 370.
15. Elliot JG, Abramson MJ, Drummer OH et al. Time to death and mast cell degranulation in fatal asthma. Respirology 2009 14: 808 813.
16. Roponen M, Yerkovich ST, Hollams E et al. Toll-like receptor 7 function is reduced in adolescents with asthma. Eur. Respir. J. 2010 35: 64 71.
17. Proud D, Turner RB, Winther B et al. Gene expression profiles during in vivo human rhinovirus infection: insights into the host response. Am. J. Respir. Crit. Care Med. 2008 178: 962 968.
18. Wark PA, Grissell T, Davies B et al. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. Respirology 2009 14: 180 186.
19. Subrata LS, Bizzintino J, Mamessier E et al. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. J. Immunol. 2009 183: 2793 2800.
20. Kuroishi S, Suda T, Fujisawa T et al. Epithelial-mesenchymal transition induced by transforming growth factor-beta1 in mouse tracheal epithelial cells. Respirology 2009 14: 828 837.
21. Shin JH, Shim JW, Kim DS et al. TGF-beta effects on airway smooth muscle cell proliferation, VEGF release and signal transduction pathways. Respirology 2009 14: 347 353.
22. Altraja S, Jaama J, Valk E et al. Changes in the proteome of human bronchial epithelial cells following stimulation with leucotriene E4 and transforming growth factor-beta1. Respirology 2009 14: 39 45.
23. Ou XM, Wen FQ, Uhal BD et al. Simvastatin attenuates experimental small airway remodelling in rats. Respirology 2009 14: 734 745.
24. Hothersall EJ, Chaudhuri R, McSharry C et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma. Thorax 2008 63: 1070 1075.
25. Kane B, Borrill Z, Southworth T et al. Reduced exhaled breath condensate pH in asthmatic smokers using inhaled corticosteroids. Respirology 2009 14: 419 423.
26. Yilmaz O, Savas R, Sogut A et al. Effectiveness of magnetic resonance angiography in the evaluation of lung perfusion in constrictive bronchiolitis obliterans. Respirology 2009 14: 295 298.
27. de Lange EE, Altes TA, Patrie JT et al. Changes in regional airflow obstruction over time in the lungs of patients with asthma: evaluation with 3He MR imaging. Radiology 2009 250: 567 575.
28. Tzeng YS, Lutchen K, Albert M. The difference in ventilation heterogeneity between asthmatic and healthy subjects quantified using hyperpolarized 3He MRI. J. Appl. Physiol. 2009 106: 813 822.
29. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008 178: 218 224.
30. Nadif R, Siroux V, Oryszczyn MP et al. Heterogeneity of asthma according to blood inflammatory patterns. Thorax 2009 64: 374 380.
31. Simpson JL, Scott R, Boyle MJ et al. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006 11: 54 61.
32. Kaminska M, Foley S, Maghni K et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J. Allergy Clin. Immunol. 2009 124: 45 51 e41-44.
33. Asano K, Nakade S, Shiomi T et al. Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics. Respirology 2009 14: 822 827.
34. Maldonado F, Pittelkow MR, Ryu JH. Constrictive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology 2009 14: 129 133.
35. Kohansal R, Martinez-Camblor P, Agusti A et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009 180: 3 10.
36. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977 1: 1645 1648.
37. Tsuda Y, Noguchi T, Mochizuki H et al. Patients with mild-to-moderate asthma may develop clinically significant chronic obstructive pulmonary disease. Respirology 2009 14: 529 536.
38. Jamrozik E, Knuiman MW, James A et al. Risk factors for adult-onset asthma: a 14-year longitudinal study. Respirology 2009 14: 814 821.
39. O'Byrne PM, Pedersen S, Lamm CJ et al. Severe exacerbations and decline in lung function in asthma. Am. J. Respir. Crit. Care Med. 2009 179: 19 24.
40. Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin. Exp. Allergy 2009 39: 1652 1658.
41. Chen CZ, Lin CC, Lee CH et al. Small airways obstruction syndrome in clinical practice. Respirology 2009 14: 393 398.
42. Habukawa C, Nagasaka Y, Murakami K et al. High-pitched breath sounds indicate airflow limitation in asymptomatic asthmatic children. Respirology 2009 14: 399 403.
43. Komatsu Y, Fujimoto K, Yasuo M et al. Airway hyper-responsiveness in young adults with asthma that remitted either during or before adolescence. Respirology 2009 14: 217 223.
44. Yelken K, Yilmaz A, Guven M et al. Paradoxical vocal fold motion dysfunction in asthma patients. Respirology 2009 14: 729 733.
45. Holmes PW, Lau KK, Crossett M et al. Diagnosis of vocal cord dysfunction in asthma with high resolution dynamic volume computerized tomography of the larynx. Respirology 2009 14: 1106 1113.
46. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 2009 180: 59 99.
47. Hart K, Weatherall M, Shirtcliffe P et al. Frequency of dosing and comparative doses of mometasone furoate: a meta-analysis. Respirology 2009 14: 1166 1172.
48. Sidana A, Singh D, Mohan A et al. Quality of life and autonomy preferences in stable asthmatics: a developing country scenario. Respirology 2009 14: 83 9.
49. Thomas M, Kay S, Pike J et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim. Care Respir. J. 2009 18: 41 9.
50. Ko FW, Leung TF, Hui DS et al. Asthma Control Test correlates well with the treatment decisions made by asthma specialists. Respirology 2009 14: 559 566.
51. Juniper EF. Validated questionnaires should not be modified. Eur. Respir. J. 2009 34: 1015 1017.
52. Ohta K, Miyamoto T, Amagasaki T et al., on behalf of the 1304 Study Group. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma. Respirology 2009 14: 1156 1165.
53. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009 360: 973 984.
54. Nair P, Pizzichini MM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009 360: 985 993.
55. Pasqualotto AC, Powell G, Niven R et al. The effects of antifungal therapy on severe asthma with fungal sensitisation and allergic bronchopulmonary aspergillosis. Respirology 2009 14: 1121 1127.
56. Denning DW, O'Driscoll BR, Powell G et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am. J. Respir. Crit. Care Med. 2009 179: 11 18.
57. Foster JM, van der Molen T, Caeser M et al. The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol. Drug Saf. 2008 17: 278 296.
58. Wise RA, Bartlett SJ, Brown ED et al. Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. J. Allergy Clin. Immunol. 2009 124: 436 444.
59. Foster JM, van Sonderen E, Lee AJ et al. A self-rating scale for patient-perceived side effects of inhaled corticosteroids. Respir. Res. 2006 7: 131.
60. Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998 113: 587 592.
61. Weatherall M, Clay J, James K et al. Dose-response relationship of inhaled corticosteroids and cataracts: a systematic review and meta-analysis. Respirology 2009 14: 983 990.
62. Bruce C, Chan HP, Mueller L et al. Effect of hydrofluoroalkane-ethanol inhalers on estimated alcohol levels in asthmatic subjects. Respirology 2009 14: 112 116.
63. Taylor DR. The beta-agonist saga and its clinical relevance: on and on it goes. Am. J. Respir. Crit. Care Med. 2009 179: 976 978.
64. Australian Centre for Asthma Monitoring. Asthma in Australia 2008. AIHW, Canberra, 2008.
65. Seale JP, Jenkins C, Wood-Baker R et al. Benefits of fixed-dose combination therapy with inhaled corticosteroids and long-acting bronchodilators as initial maintenance therapy in the management of asthma. Respirology 2009 14: 224 229.
66. Wang JS, Hung WP. The effects of a swimming intervention for children with asthma. Respirology 2009 14: 838 842.
67. Uyan ZS, Carraro S, Piacentini G et al. Swimming pool, respiratory health, and childhood asthma: should we change our beliefs? Pediatr. Pulmonol. 2009 44: 31 7.
68. Camargo CA Jr., Rachelefsky G, Schatz M et al. Managing asthma exacerbations in the emergency department: summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines for the management of asthma exacerbations. J. Allergy Clin. Immunol. 2009 124: S5 14.
69. Oborne J, Mortimer K, Hubbard RB et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am. J. Respir. Crit. Care Med. 2009 180: 598 602.
70. Innes AL, Carrington SD, Thornton DJ et al. Ex vivo sputum analysis reveals impairment of protease-dependent mucus degradation by plasma proteins in acute asthma. Am. J. Respir. Crit. Care Med. 2009 180: 203 210.
71. Daviskas E, Anderson SD, Young IH et al. Inhaled mannitol changes the sputum properties in asthmatics with mucus hypersecretion. Respirology 2007 12: 683 691.
72. Reddel HK. Characterizing asthma phenotypes: predictors and outcomes at the extremes of asthma severity. Respirology 2009 14: 778 780.
73. Pant S, Walters EH, Griffiths A et al. Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD. Respirology 2009 14: 495 503.
74. Hogg JC, van Eeden S. Pulmonary and systemic response to atmospheric pollution. Respirology 2009 14: 336 346.
75. Antonelli-Incalzi R, Pedone C. COPD: more than respiratory. Lancet 2008 371: 26 7 author reply 28.
76. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004 350: 1005 1012.
77. Liu S-F, Chin C-H, Wang C-C et al. Correlation between serum biomarkers and BODE index in patients with stable COPD. Respirology 2009 14: 999 1004.
78. Nogawa H, Ishibashi Y, Ogawa A et al. Carbocisteine can scavenge reactive oxygen species in vitro. Respirology 2009 14: 53 9.
79. Tatsumi K, Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2007 55: 1884 1886.
80. Yasuda H, Yamaya M, Sasaki T et al. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2006 54: 378 380.
81. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998 273: 30336 30343.
82. Cai S, Chen P, Zhang C et al. Oral N-acetylcysteine attenuates pulmonary emphysema and alveolar septal cell apoptosis in smoking-induced COPD in rats. Respirology 2009 14: 354 359.
83. Yoshida M, Nakayama K, Yasuda H et al. Carbocisteine inhibits oxidant-induced apoptosis in cultured human airway epithelial cells. Respirology 2009 14: 1027 1034.
84. Yang IA, Francis SM. Deconstructing COPD using genomic tools. Respirology 2009 14: 313 317.
85. Spira A, Beane J, Shah V et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. USA 2004 101: 10143 10148. (Pubitemid 38891209)
86. Savarimuthu Francis SM, Larsen JE, Pavey SJ et al. Expression profiling identifies genes involved in emphysema severity. Respir. Res. 2009 10: 81.
87. Kim WJ, Sheen SS, Kim TH et al. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. Respirology 2009 14: 260 263.
88. Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 2004 13: 1353 1359.
89. Lasky-Su J, Lyon HN, Emilsson V et al. On the replication of genetic associations: timing can be everything! Am. J. Hum. Genet. 2008 82: 849 858.
90. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009 374: 721 732.
91. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009 374: 733 743.
92. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007 370: 741 750.
93. Tan WC, Seale P, Ip M et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology 2009 14: 90 7.
94. Lin K, Watkins B, Johnson T et al. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 2008 148: 535 543.
95. Coxson HO, Mayo J, Lam S et al. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009 180: 588 597.
96. Omori H, Tsuji M, Sata K et al. Correlation of C-reactive protein with disease severity in CT diagnosed emphysema. Respirology 2009 14: 551 558.
97. Yoza Y, Ariyoshi K, Honda S et al. Development of an activity of daily living scale for patients with COPD: the Activity of Daily Living Dyspnoea scale. Respirology 2009 14: 429 435.
98. Jones PW, Harding G, Berry P et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009 34: 648 654.
99. Strassmann R, Bausch B, Spaar A et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur. Respir. J. 2009 34: 634 640.
100. Wang C, Xiao D, Chan KP et al. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology 2009 14: 384 392.
101. Mckenzie DK, Abramson M, Crockett AJ et al. on behalf of The Australian Lung Foundation. The COPD-X Plan: Australian and New Zealand Guidelines for the Management of Chronic Obstructive Pulmonary Disease 2009. [Accessed 07 Jan 2010] URL: http://www/copdx.org.au/guidelines.index.asp.
102. Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008 359: 1543 1554.
103. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007 356: 775 789.
104. Yang IA, Fong KM, Sim EHA et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007 2 Art No: CD002991. DOI: 101002/14651858CD002991pub2.
105. Kurashima K, Hara K, Yoneda K et al. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone. Respirology 2009 14: 239 244.
106. Wu Q, Li G, Lei WI et al. The efficacy and safety of tiotropium in Chinese patients with stable chronic obstructive pulmonary disease: a meta-analysis. Respirology 2009 14: 666 674.
107. Kobayashi S, Suzuki S, Niikawa H et al. Preoperative use of inhaled tiotropium in lung cancer patients with untreated COPD. Respirology 2009 14: 675 679.
108. Black PN. Tiotropium-lessons from recent studies. Respirology 2009 14: 623 624.
109. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008 300: 1439 1450.
110. Sin DD, Tashkin D, Zhang X et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009 374: 712 719.
111. Crim C, Calverley PM, Anderson JA et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur. Respir. J. 2009 34: 641 647.
112. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch. Intern. Med. 2009 169: 219 229.
113. Calverley PM, Rabe KF, Goehring UM et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009 374: 685 694.
114. Fabbri LM, Calverley PM, Izquierdo-Alonso JL et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009 374: 695 703.
115. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N. Engl. J. Med. 2009 360: 1329 1335.
116. Eaton T, Young P, Fergusson W et al. Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology 2009 14: 230 238.
117. Serginson J, Yang IA, Armstrong J et al. Variability in the rate of prescription and cost of domiciliary oxygen therapy in Australia. Med. J. Aust. 2009 191: 549 553.
118. Moore R, Berlowitz D, Pretto J et al. Acute effects of hyperoxia on resting pattern of ventilation and dyspnoea in COPD. Respirology 2009 14: 545 550.
119. Borghi-Silva A, Di Thommazo L, Pantoni CB et al. Non-invasive ventilation improves peripheral oxygen saturation and reduces fatigability of quadriceps in patients with COPD. Respirology 2009 14: 537 544.
120. Tsujino K, Sasada S, Kodama M et al. Severe bullous emphysema and hypercapnia successfully treated by bronchoscopic lung volume reduction. Respirology 2009 14: 907 909.
121. Kodric M, Garuti G, Colomban M et al. The effectiveness of a bronchial drainage technique (ELTGOL) in COPD exacerbations. Respirology 2009 14: 424 428.
122. El-Attar M, Said M, El-Assal G et al. Serum trace element levels in COPD patient: the relation between trace element supplementation and period of mechanical ventilation in a randomized controlled trial. Respirology 2009 14: 1180 1187.
123. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007 29: 1224 1238.
124. Burgel PR, Nesme-Meyer P, Chanez P et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009 135: 975 982.
125. Terada K, Muro S, Ohara T et al. Cough-reflex sensitivity to inhaled capsaicin in COPD associated with increased exacerbation frequency. Respirology 2009 14: 1151 1155.
126. Tsimogianni AM, Papiris SA, Kanavaki S et al. Predictors of positive sputum cultures in exacerbations of chronic obstructive pulmonary disease. Respirology 2009 14: 1114 1120.
127. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit. Care Med. 2008 36: 941 952.
128. Rammaert B, Verdier N, Cavestri B et al. Procalcitonin as a prognostic factor in severe acute exacerbation of chronic obstructive pulmonary disease. Respirology 2009 14: 969 974.
129. Puhan MA, Garcia-Aymerich J, Frey M et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009 374: 704 711.
130. Miller A, Strauss BJ, Mol S et al. Dual-energy X-ray absorptiometry is the method of choice to assess body composition in COPD. Respirology 2009 14: 411 418.
131. Antonelli-Incalzi R, Pedone C, Scarlata S et al. Correlates of mortality in elderly COPD patients: focus on health-related quality of life. Respirology 2009 14: 98 104.